Inhibitors of poly(ADP-ribose) polymerase (PARP) have transformed the treatment of patients with BRCA-mutant breast and ovarian cancers, which typically develop in a background of germline mutations in BRCA1 or BRCA2. Here, PARP1 is linked to ovarian cancer.